Solara Active Pharma Sciences · risk themes across the available quarters.
Bear-case history
Management delayed all corporate actions and deferred the planned Visak demerger while evaluating ibuprofen options. The strategic review outcome remains unknown, creating material uncertainty around the company's future structure and capital allocation.
Analyst Anupam Chan directly questioned why ibuprofen numbers were not disclosed earlier, noting gross margins have dropped 800 basis points between last year and this year. Management acknowledged this is the lowest gross margin reported in recent quarters.
Arun disclosed that Solara can now only sell ibuprofen to Big Pharma customers, limiting addressable market. These marquee customers are aware of Solara's cost disadvantage and have aligned with current pricing, suggesting limited room for margin recovery.
When asked about FY27 growth targets for the API growth business and the One Source product launch revenue opportunity, management explicitly declined to provide specifics, stating they will share guidance along with the ibuprofen decision.
Ibuprofen recorded negative EBITDA again; strategic options may not yield favorable outcome, prolonging losses.
Despite ₹200 crore R&D spend over 4-5 years, no new profitable product launched; new DMFs will only commercialize from FY29.
Vizag site mothballed since 2024 incurs ₹12-15 crore annual maintenance cost with no revenue.
Top 15-20 products contribute 75-80% of base business revenue; loss of any key customer could impact performance.